I wonder if Nadar ever wanted to say to some of th
Post# of 153887
(Total Views: 759)
Posted On: 01/18/2022 9:28:34 PM
I wonder if Nadar ever wanted to say to some of the CytoDyn investors, “get off my back!”
I find it funny that a lot of the investors complain that the company shouldn’t release news until they have some concrete news. Then if 4 or 5 days go by without news, the same people are pacing the floor.
I kind of enjoy the down time without news. Sometimes weeks go by and I don’t look at the share price. It’s kind of liberating.
I am all in for CytoDyn, and excited to see where Leronlimab is in a few years.
One way or another 700mg NASH results should be interesting.
Looking forward to Longhaulers trial, and oncology to continue. The HIV cure project they talked about should be rolling soon. Also hiv prep. Oh and the MD Anderson study with Leronlimab in combination with CAR T therapy. A lot of good things in the next few years. If 700mg NASH results are as good as we think, maybe MERK will jump on it, as a replacement for their junk CCR5 drug. MERK has spent a lot of money researching CCR5, seems like it would be beneficial to them to have the premiere CCR5 monoclonal antibody that is Leronlimab.
I find it funny that a lot of the investors complain that the company shouldn’t release news until they have some concrete news. Then if 4 or 5 days go by without news, the same people are pacing the floor.
I kind of enjoy the down time without news. Sometimes weeks go by and I don’t look at the share price. It’s kind of liberating.
I am all in for CytoDyn, and excited to see where Leronlimab is in a few years.
One way or another 700mg NASH results should be interesting.
Looking forward to Longhaulers trial, and oncology to continue. The HIV cure project they talked about should be rolling soon. Also hiv prep. Oh and the MD Anderson study with Leronlimab in combination with CAR T therapy. A lot of good things in the next few years. If 700mg NASH results are as good as we think, maybe MERK will jump on it, as a replacement for their junk CCR5 drug. MERK has spent a lot of money researching CCR5, seems like it would be beneficial to them to have the premiere CCR5 monoclonal antibody that is Leronlimab.
(12)
(0)